| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Acorda Therapeutics Inc (NASDAQ: ACOR)
ACOR Technical Analysis
5
| As on 9th Jun 2023 ACOR SHARE Price closed @ 10.03 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 1.07 & Strong Buy for SHORT-TERM with Stoploss of 2.11 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ACORSHARE Price
| Open | 10.62 | Change | Price | % |
| High | 10.76 | 1 Day | -0.81 | -7.47 |
| Low | 10.01 | 1 Week | 9.44 | 1600.00 |
| Close | 10.03 | 1 Month | 9.58 | 2128.89 |
| Volume | 14800 | 1 Year | 7.48 | 293.33 |
| 52 Week High 11.64 | 52 Week Low 0.28 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ACOR Daily Charts |
ACOR Intraday Charts |
Whats New @ Bazaartrend |
ACOR Free Analysis |
|
|
ACOR Important Levels Intraday
| RESISTANCE | 11.48 |
| RESISTANCE | 11.01 |
| RESISTANCE | 10.73 |
| RESISTANCE | 10.44 |
| SUPPORT | 9.62 |
| SUPPORT | 9.33 |
| SUPPORT | 9.05 |
| SUPPORT | 8.58 |
ACOR Forecast April 2024
| 4th UP Forecast | 11.76 |
| 3rd UP Forecast | 11.21 |
| 2nd UP Forecast | 10.86 |
| 1st UP Forecast | 10.52 |
| 1st DOWN Forecast | 9.54 |
| 2nd DOWN Forecast | 9.2 |
| 3rd DOWN Forecast | 8.85 |
| 4th DOWN Forecast | 8.3 |
ACOR Weekly Forecast
| 4th UP Forecast | 10.51 |
| 3rd UP Forecast | 10.36 |
| 2nd UP Forecast | 10.26 |
| 1st UP Forecast | 10.17 |
| 1st DOWN Forecast | 9.89 |
| 2nd DOWN Forecast | 9.80 |
| 3rd DOWN Forecast | 9.70 |
| 4th DOWN Forecast | 9.55 |
ACOR Forecast2024
| 4th UP Forecast | 33.48 |
| 3rd UP Forecast | 25.96 |
| 2nd UP Forecast | 21.31 |
| 1st UP Forecast | 16.66 |
| 1st DOWN Forecast | 3.4 |
| 2nd DOWN Forecast | -1.25 |
| 3rd DOWN Forecast | -5.9 |
| 4th DOWN Forecast | -13.42 |
Acorda Therapeutics Inc ( NASDAQ USA Symbol : ACOR )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ACOR Business Profile
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York. Address: 420 Saw Mill River Road, Ardsley, NY, United States, 10502
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service